leadf
logo-loader
viewOkyo Pharma Ltd
(
LSE:OKYOFRA:OK1OTCQB:EMMLF
)

OKYO Pharma sees big opportunities for its dry eye and pain management technology

Kunwar Shailubhai, chief scientific officer of OKYO Pharma Plc (LON:OKYO), discusses with Proactive's Andrew Scott the new direction and investment strategy for the business following its name change earlier this year.

He says they've found two 'exciting' new technologies focused on dry eye and pain management.

"Both are worldwide epidemics ... we think there's a lot of opportunity'', he says.

Quick facts: Okyo Pharma Ltd

Follow
LSE:OKYO

Price: 4.4 GBX

Market Cap: £42.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

OKYO Pharma announces key engagement with Ora Inc to develop its novel dry...

OKYO Pharma Limited's (LON:OKYO)(OTCQB:EMMLF) CEO Dr Gary Jacob tells Proactive's Andrew Scott they've engaged Ora Inc, a world-class ophthalmology contract research organization, to guide the upcoming product development and lead the regulatory strategy for OK-101. The drug is OKYO's lead...

on 29/6/21

2 min read